Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBT (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of EBT data on record, last reported at -$122.5 million in Q4 2025.

  • For Q4 2025, EBT fell 52.42% year-over-year to -$122.5 million; the TTM value through Dec 2025 reached -$464.8 million, down 56.27%, while the annual FY2025 figure was -$465.1 million, 56.12% down from the prior year.
  • EBT reached -$122.5 million in Q4 2025 per CRNX's latest filing, up from -$130.1 million in the prior quarter.
  • Across five years, EBT topped out at -$22.9 million in Q1 2021 and bottomed at -$130.1 million in Q3 2025.
  • Average EBT over 5 years is -$62.1 million, with a median of -$53.4 million recorded in 2023.
  • Peak YoY movement for EBT: fell 20.23% in 2023, then tumbled 69.33% in 2025.
  • A 5-year view of EBT shows it stood at -$30.8 million in 2021, then tumbled by 48.18% to -$45.7 million in 2022, then dropped by 22.53% to -$55.9 million in 2023, then plummeted by 43.69% to -$80.4 million in 2024, then plummeted by 52.42% to -$122.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$122.5 million in Q4 2025, -$130.1 million in Q3 2025, and -$115.7 million in Q2 2025.